Cardiovasc Ther:STEMI患者PCI后全剂量比伐卢定灌注能否预防急性支架血栓?

2017-06-26 顾歆纯 吴星 环球医学

ST段抬高心梗(STEMI)患者经皮冠状动脉介入术(PCI)后全剂量比伐卢定灌注对急性支架血栓(ST)有何影响?2017年6月,发表在《Cardiovasc Ther.》的一项多中心、回顾性、观察研究表明,在真实世界行直接PCI的STEMI患者中,PCI后全剂量比伐卢定灌注较为安全,且有预防急性ST的趋势。

ST段抬高心梗(STEMI)患者经皮冠状动脉介入术(PCI)后全剂量比伐卢定灌注对急性支架血栓(ST)有何影响?2017年6月,发表在《Cardiovasc Ther.》的一项多中心、回顾性、观察研究表明,在真实世界行直接PCI的STEMI患者中,PCI后全剂量比伐卢定灌注较为安全,且有预防急性ST的趋势。

目的:该研究旨在评价真实世界STEMI人群延长全剂量比伐卢定灌注的影响。

背景:亚组数据和来自随机临床试验的荟萃分析显示,术后全剂量灌注(1.75 mg/kg/h)比伐卢定对于减弱直接PCI术后急性ST显示出潜力。

方法:在该项多中心、回顾性、观察研究中,纳入2013年7月至2016年5月期间,在中国65个医学中心,直接PCI期间接受比伐卢定的2047例序贯STEMI患者。主要结局指标为急性ST,定义为手术后美国学术研究协会(ARC)明确/可能,次要终点指标包括总ST、重大不良心脑血管事件(MACCE,定义为死亡、再梗死、卒中和靶血管血运重建),以及30天任何出血。

结果:在2047例STEMI患者中,1123例(54.9%)患者术后使用比伐卢定全剂量灌注(中位时间120分钟),而其他924例(45.1%)患者使用低剂量(0.25 mg/kg/h)或术后无灌注。无灌注或低剂量比伐卢定延长灌注患者中共发生3次急性ST(0.3%),但没有在PCI后进行全剂量灌注的患者中观察到急性ST(0.3% vs 0.0%,P=0.092)。30天MACCE(2.1% vs 2.7%,P=0.402)和总出血(2.1% vs 1.4%,P=0.217)方面的结局显示,两组间没有显着差异,没有观察到亚急性ST。

结论:在真实世界行直接PCI的STEMI患者中,PCI后全剂量比伐卢定灌注较为安全,且有预防急性ST的趋势。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1938727, encodeId=b4011938e2777, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Feb 24 05:17:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936707, encodeId=d96a1936e072f, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Dec 23 08:17:00 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667771, encodeId=7675166e77118, content=<a href='/topic/show?id=676c636260c' target=_blank style='color:#2F92EE;'>#比伐卢定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63626, encryptionId=676c636260c, topicName=比伐卢定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a96426178489, createdName=Luyuxie_18, createdTime=Mon Sep 11 18:17:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481995, encodeId=3a62148199591, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Wed Jun 28 08:17:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582569, encodeId=4dee158256935, content=<a href='/topic/show?id=c1695e118ac' target=_blank style='color:#2F92EE;'>#支架血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57118, encryptionId=c1695e118ac, topicName=支架血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b83016955660, createdName=ms1779634646866130, createdTime=Wed Jun 28 08:17:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215926, encodeId=9d2621592605, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ae02063908, createdName=152****8376, createdTime=Tue Jun 27 10:19:29 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215681, encodeId=740e215681ad, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jun 26 19:23:19 CST 2017, time=2017-06-26, status=1, ipAttribution=)]
    2018-02-24 quxin068
  2. [GetPortalCommentsPageByObjectIdResponse(id=1938727, encodeId=b4011938e2777, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Feb 24 05:17:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936707, encodeId=d96a1936e072f, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Dec 23 08:17:00 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667771, encodeId=7675166e77118, content=<a href='/topic/show?id=676c636260c' target=_blank style='color:#2F92EE;'>#比伐卢定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63626, encryptionId=676c636260c, topicName=比伐卢定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a96426178489, createdName=Luyuxie_18, createdTime=Mon Sep 11 18:17:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481995, encodeId=3a62148199591, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Wed Jun 28 08:17:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582569, encodeId=4dee158256935, content=<a href='/topic/show?id=c1695e118ac' target=_blank style='color:#2F92EE;'>#支架血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57118, encryptionId=c1695e118ac, topicName=支架血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b83016955660, createdName=ms1779634646866130, createdTime=Wed Jun 28 08:17:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215926, encodeId=9d2621592605, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ae02063908, createdName=152****8376, createdTime=Tue Jun 27 10:19:29 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215681, encodeId=740e215681ad, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jun 26 19:23:19 CST 2017, time=2017-06-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1938727, encodeId=b4011938e2777, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Feb 24 05:17:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936707, encodeId=d96a1936e072f, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Dec 23 08:17:00 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667771, encodeId=7675166e77118, content=<a href='/topic/show?id=676c636260c' target=_blank style='color:#2F92EE;'>#比伐卢定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63626, encryptionId=676c636260c, topicName=比伐卢定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a96426178489, createdName=Luyuxie_18, createdTime=Mon Sep 11 18:17:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481995, encodeId=3a62148199591, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Wed Jun 28 08:17:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582569, encodeId=4dee158256935, content=<a href='/topic/show?id=c1695e118ac' target=_blank style='color:#2F92EE;'>#支架血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57118, encryptionId=c1695e118ac, topicName=支架血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b83016955660, createdName=ms1779634646866130, createdTime=Wed Jun 28 08:17:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215926, encodeId=9d2621592605, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ae02063908, createdName=152****8376, createdTime=Tue Jun 27 10:19:29 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215681, encodeId=740e215681ad, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jun 26 19:23:19 CST 2017, time=2017-06-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1938727, encodeId=b4011938e2777, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Feb 24 05:17:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936707, encodeId=d96a1936e072f, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Dec 23 08:17:00 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667771, encodeId=7675166e77118, content=<a href='/topic/show?id=676c636260c' target=_blank style='color:#2F92EE;'>#比伐卢定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63626, encryptionId=676c636260c, topicName=比伐卢定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a96426178489, createdName=Luyuxie_18, createdTime=Mon Sep 11 18:17:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481995, encodeId=3a62148199591, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Wed Jun 28 08:17:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582569, encodeId=4dee158256935, content=<a href='/topic/show?id=c1695e118ac' target=_blank style='color:#2F92EE;'>#支架血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57118, encryptionId=c1695e118ac, topicName=支架血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b83016955660, createdName=ms1779634646866130, createdTime=Wed Jun 28 08:17:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215926, encodeId=9d2621592605, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ae02063908, createdName=152****8376, createdTime=Tue Jun 27 10:19:29 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215681, encodeId=740e215681ad, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jun 26 19:23:19 CST 2017, time=2017-06-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1938727, encodeId=b4011938e2777, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Feb 24 05:17:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936707, encodeId=d96a1936e072f, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Dec 23 08:17:00 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667771, encodeId=7675166e77118, content=<a href='/topic/show?id=676c636260c' target=_blank style='color:#2F92EE;'>#比伐卢定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63626, encryptionId=676c636260c, topicName=比伐卢定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a96426178489, createdName=Luyuxie_18, createdTime=Mon Sep 11 18:17:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481995, encodeId=3a62148199591, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Wed Jun 28 08:17:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582569, encodeId=4dee158256935, content=<a href='/topic/show?id=c1695e118ac' target=_blank style='color:#2F92EE;'>#支架血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57118, encryptionId=c1695e118ac, topicName=支架血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b83016955660, createdName=ms1779634646866130, createdTime=Wed Jun 28 08:17:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215926, encodeId=9d2621592605, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ae02063908, createdName=152****8376, createdTime=Tue Jun 27 10:19:29 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215681, encodeId=740e215681ad, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jun 26 19:23:19 CST 2017, time=2017-06-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1938727, encodeId=b4011938e2777, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Feb 24 05:17:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936707, encodeId=d96a1936e072f, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Dec 23 08:17:00 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667771, encodeId=7675166e77118, content=<a href='/topic/show?id=676c636260c' target=_blank style='color:#2F92EE;'>#比伐卢定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63626, encryptionId=676c636260c, topicName=比伐卢定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a96426178489, createdName=Luyuxie_18, createdTime=Mon Sep 11 18:17:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481995, encodeId=3a62148199591, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Wed Jun 28 08:17:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582569, encodeId=4dee158256935, content=<a href='/topic/show?id=c1695e118ac' target=_blank style='color:#2F92EE;'>#支架血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57118, encryptionId=c1695e118ac, topicName=支架血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b83016955660, createdName=ms1779634646866130, createdTime=Wed Jun 28 08:17:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215926, encodeId=9d2621592605, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ae02063908, createdName=152****8376, createdTime=Tue Jun 27 10:19:29 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215681, encodeId=740e215681ad, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jun 26 19:23:19 CST 2017, time=2017-06-26, status=1, ipAttribution=)]
    2017-06-27 152****8376

    谢谢分享受益匪浅

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1938727, encodeId=b4011938e2777, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Feb 24 05:17:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936707, encodeId=d96a1936e072f, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Dec 23 08:17:00 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667771, encodeId=7675166e77118, content=<a href='/topic/show?id=676c636260c' target=_blank style='color:#2F92EE;'>#比伐卢定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63626, encryptionId=676c636260c, topicName=比伐卢定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a96426178489, createdName=Luyuxie_18, createdTime=Mon Sep 11 18:17:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481995, encodeId=3a62148199591, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Wed Jun 28 08:17:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582569, encodeId=4dee158256935, content=<a href='/topic/show?id=c1695e118ac' target=_blank style='color:#2F92EE;'>#支架血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57118, encryptionId=c1695e118ac, topicName=支架血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b83016955660, createdName=ms1779634646866130, createdTime=Wed Jun 28 08:17:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215926, encodeId=9d2621592605, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ae02063908, createdName=152****8376, createdTime=Tue Jun 27 10:19:29 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215681, encodeId=740e215681ad, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jun 26 19:23:19 CST 2017, time=2017-06-26, status=1, ipAttribution=)]
    2017-06-26 131****1460

    学习了受益匪浅。

    0

相关资讯

Chin Circul J:血小板—中性粒细胞聚集体或可作为预测STEMI的新指标

临床上有约1/4的急性ST段抬高型心肌梗死(STEMI)早期发病症状不典型,有没有什么新手段帮助从中将其甄别出来?众所周知,在急性心梗发作时,血小板和白细胞在其中也很“忙乎”。青岛大学医学院附属烟台毓璜顶医院任法新、董海秋等研究发现,血小板-白细胞聚集体,尤其是血小板—中性粒细胞聚集体的升高,或可作为预测STEMI的新指标。研究显示,STEMI患者中血小板-白细胞聚集体,包括血小板—中性粒细胞聚集

NEJM:血流储备分数指导的多支血管成形术在心肌梗死中的运用!

对于已经在梗死相关动脉进行PCI的STEMI和多支血管病变患者,在急性期FFR指导的非梗死相关动脉完全性血运重建会发生复合心血管终点风险,但低于在那些只处理梗死相关动脉患者的风险。

KIDNEY INT:急性肾损伤与心肌梗死后微血管心肌损害有关!

因此,在血管再通的STEMI患者中,采用CMR评估的微血管损伤存在与AKI风险增加独立相关。这意味着心脏微血管病变与STEMI之后发生的肾损伤之间存在一个潜在的病理生理学联系。

Eur Heart J:心肌梗死后自体骨髓细胞移植效果如何?

由此可见,BOOST-2试验不支持在STEMI患者使用有核BMCs治疗。

Circulation:早期使用NAC和NTG治疗可以减少STEMI患者PCI术后心肌梗死面积!

由此可见,大剂量静脉注射NAC同时接受低剂量静脉注射NTG与STEMI患者PCI术后心肌梗死面积减少相关。需要一个更大型的研究来评估这种疗法对临床心脏结局的影响。

JAHA:左心室肥厚与接受经皮冠状动脉介入治疗的STEMI患者的梗死面积增大有关!

在经皮冠状动脉介入治疗的STEMI患者中,LVH与较大的心肌梗死面积、较少的心肌挽救、较高的微血管阻塞、较低的LVEF、较高的死亡率和心力衰竭发生风险独立相关。